Baxter International Management
Management criteria checks 2/4
Baxter International's CEO is Joe Almeida, appointed in Jan 2016, has a tenure of 8.25 years. total yearly compensation is $13.79M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $22.93M. The average tenure of the management team and the board of directors is 1.9 years and 4.2 years respectively.
Key information
Joe Almeida
Chief executive officer
US$13.8m
Total compensation
| CEO salary percentage | 9.4% |
| CEO tenure | 8.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.9yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14
Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 05Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price
Apr 24Is Baxter International (NYSE:BAX) Using Too Much Debt?
Apr 03Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 18Investors Could Be Concerned With Baxter International's (NYSE:BAX) Returns On Capital
Feb 10Baxter International: Another YoY Earnings Decline Expected, Shares Tag Support
Feb 03Why Baxter Is One Of My #1 2023 Bets For Healthcare/Medtech
Jan 02An Intrinsic Calculation For Baxter International Inc. (NYSE:BAX) Suggests It's 32% Undervalued
Dec 30Baxter cut to hold at Deutsche Bank on inflation pressures
Dec 15Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Nov 18Baxter International: Despite Weakening On The Bottom Line, Shares Look Attractive
Oct 24Here's What's Concerning About Baxter International's (NYSE:BAX) Returns On Capital
Oct 05Baxter is said to evaluate sale of two of its kidney businesses
Sep 14Baxter reaches 52-week low; stock down 34% YTD
Aug 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$14m | US$1m | -US$76m |
| Sep 30 2023 | n/a | n/a | US$225m |
| Jun 30 2023 | n/a | n/a | -US$3b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$14m | US$1m | -US$3b |
| Sep 30 2022 | n/a | n/a | -US$3b |
| Jun 30 2022 | n/a | n/a | US$876m |
| Mar 31 2022 | n/a | n/a | US$992m |
| Dec 31 2021 | US$16m | US$1m | US$1b |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$1b |
| Mar 31 2021 | n/a | n/a | US$1b |
| Dec 31 2020 | US$16m | US$1m | US$1b |
| Sep 30 2020 | n/a | n/a | US$911m |
| Jun 30 2020 | n/a | n/a | US$924m |
| Mar 31 2020 | n/a | n/a | US$991m |
| Dec 31 2019 | US$14m | US$1m | US$1b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$16m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$1b |
| Jun 30 2018 | n/a | n/a | US$795m |
| Mar 31 2018 | n/a | n/a | US$840m |
| Dec 31 2017 | US$15m | US$1m | US$609m |
Compensation vs Market: Joe's total compensation ($USD13.79M) is about average for companies of similar size in the US market ($USD13.51M).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
CEO
Joe Almeida (61 yo)
8.3yrs
Tenure
US$13,786,671
Compensation
Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 8.3yrs | US$13.79m | 0.11% $ 22.9m | |
| Executive VP & CFO | less than a year | US$5.37m | 0% $ 0 | |
| Executive VP & Group President of Medical Products and Therapies | 1.1yrs | US$4.86m | 0.031% $ 6.5m | |
| Executive VP & Group President of Pharmaceuticals | 1.8yrs | US$3.87m | 0.0016% $ 319.7k | |
| Executive VP & Group President of Kidney Care | less than a year | US$9.64m | 0% $ 0 | |
| Senior VP and Chief Medical & Scientific Officer | 1.3yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive VP & General Counsel | 2yrs | US$5.66m | 0.0014% $ 286.9k | |
| ?Senior Vice President | no data | no data | no data | |
| ?Executive VP & Chief Human Resources Officer | 6.9yrs | US$4.14m | 0.037% $ 7.6m | |
| Executive VP & Chief Supply Chain Officer | 4.3yrs | no data | 0.0030% $ 612.7k | |
| Executive VP & Group President of Healthcare Systems and Technologies | 2.3yrs | no data | 0.021% $ 4.4m |
1.9yrs
Average Tenure
56yo
Average Age
Experienced Management: BAX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 8.3yrs | US$13.79m | 0.11% $ 22.9m | |
| Independent Director | less than a year | US$197.82k | 0.00061% $ 125.0k | |
| Chairman Emeritus | 8.3yrs | US$17.88m | no data | |
| Independent Director | 1.9yrs | US$349.64k | 0.0014% $ 293.0k | |
| Independent Director | 7.2yrs | US$373.98k | 0.0043% $ 877.0k | |
| Independent Director | 5.2yrs | US$364.98k | 0.0030% $ 616.8k | |
| Independent Director | 2.3yrs | US$363.00k | 0.00015% $ 30.7k | |
| Independent Director | 7.3yrs | US$367.31k | 0.0032% $ 663.9k | |
| Lead Independent Director | 1.9yrs | US$382.31k | 0.0014% $ 291.0k | |
| Independent Director | 3.2yrs | US$357.00k | 0.00054% $ 110.7k | |
| Independent Director | less than a year | US$226.35k | 0.00076% $ 155.7k | |
| Independent Director | 5.2yrs | US$352.98k | no data |
4.2yrs
Average Tenure
65yo
Average Age
Experienced Board: BAX's board of directors are considered experienced (4.2 years average tenure).